Introduction: Adalimumab is effective in inducing and maintaining response/remission in patients with Crohn’s Disease (CD) either naive to biological therapies or following secondary failure of infliximab. Aim: To present the first ‘real-life’ survey data from England and Ireland on the use of adalimumab. Method: A retrospective audit conducted by a web-based questionnaire in England/Ireland. Results: We analysed data on 61 patients (35 female) with a median age of 33 years (range 17-71) with average follow-up of 8 months. Maximal maintenance dose was 40mg every other week in 84% of patients, 40mg weekly in 13% and 80mg weekly in 3%. Maintenance adalimumab achieved remission in 57% of patients. The ongoing response rate was 83.6%. An additional 8% had a secondary loss of response after average of 8.4 months (range 2-17). 23% had adverse effects, of which local pain 29%, infection 36%, headaches 14%, leucopenia (on AZA) 7%, a painful rash 7%, serum-sickness type reaction 7%. Adverse events led to discontinuation in 2 patients. Conclusion: This English/Irish audit show acceptable response/remission and safety profile of adalimumab in the treatment of CD. In contrast to previous data from Scotland, dose escalation was only seen in 16% of patients. The majority of responders were steroid-free at follow-up.

Iacucci, M. (2010). Survey regarding the use of adalimumab as maintenance therapy in Crohn’s disease in England and Ireland.

Survey regarding the use of adalimumab as maintenance therapy in Crohn’s disease in England and Ireland

IACUCCI, MARIETTA
2010-08-09

Abstract

Introduction: Adalimumab is effective in inducing and maintaining response/remission in patients with Crohn’s Disease (CD) either naive to biological therapies or following secondary failure of infliximab. Aim: To present the first ‘real-life’ survey data from England and Ireland on the use of adalimumab. Method: A retrospective audit conducted by a web-based questionnaire in England/Ireland. Results: We analysed data on 61 patients (35 female) with a median age of 33 years (range 17-71) with average follow-up of 8 months. Maximal maintenance dose was 40mg every other week in 84% of patients, 40mg weekly in 13% and 80mg weekly in 3%. Maintenance adalimumab achieved remission in 57% of patients. The ongoing response rate was 83.6%. An additional 8% had a secondary loss of response after average of 8.4 months (range 2-17). 23% had adverse effects, of which local pain 29%, infection 36%, headaches 14%, leucopenia (on AZA) 7%, a painful rash 7%, serum-sickness type reaction 7%. Adverse events led to discontinuation in 2 patients. Conclusion: This English/Irish audit show acceptable response/remission and safety profile of adalimumab in the treatment of CD. In contrast to previous data from Scotland, dose escalation was only seen in 16% of patients. The majority of responders were steroid-free at follow-up.
A.A. 2009/2010
Gastroenterologia
21.
adalimumab
anti-TNF
Crohn’s disease
survey
response/remission
Settore MED/12 - Gastroenterologia
English
Tesi di dottorato
Iacucci, M. (2010). Survey regarding the use of adalimumab as maintenance therapy in Crohn’s disease in England and Ireland.
File in questo prodotto:
File Dimensione Formato  
PhD thesis adalimumab in CD.pdf

accesso aperto

Dimensione 223.23 kB
Formato Adobe PDF
223.23 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/1420
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact